Leerink Partnrs Reduces Earnings Estimates for Schrödinger

Schrödinger, Inc. (NASDAQ:SDGR) – Investment analysts at Leerink Partnrs dropped their FY2024 earnings per share estimates for Schrödinger in a report released on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings of ($2.11) per share for the year, down from their previous forecast of ($1.99). The consensus estimate for Schrödinger’s current full-year earnings is ($2.29) per share. Leerink Partnrs also issued estimates for Schrödinger’s Q4 2024 earnings at ($0.09) EPS, FY2025 earnings at ($2.16) EPS and FY2026 earnings at ($2.73) EPS.

Schrödinger (NASDAQ:SDGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.12). The firm had revenue of $35.30 million for the quarter, compared to analysts’ expectations of $41.25 million. Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. Schrödinger’s quarterly revenue was down 17.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.86) earnings per share.

A number of other research analysts also recently commented on the company. BMO Capital Markets boosted their target price on Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 13th. KeyCorp raised their price objective on shares of Schrödinger from $25.00 to $27.00 and gave the company an “overweight” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.10.

Schrödinger Stock Up 1.1 %

SDGR stock opened at $24.67 on Friday. The company has a 50 day moving average of $20.71 and a two-hundred day moving average of $20.08. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -10.54 and a beta of 1.59. Schrödinger has a 12-month low of $16.67 and a 12-month high of $33.63.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Massachusetts Financial Services Co. MA raised its stake in Schrödinger by 58.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 1,945,182 shares of the company’s stock valued at $36,083,000 after purchasing an additional 717,059 shares during the last quarter. Rubric Capital Management LP lifted its stake in shares of Schrödinger by 17.7% in the third quarter. Rubric Capital Management LP now owns 3,685,503 shares of the company’s stock valued at $68,366,000 after buying an additional 555,503 shares during the period. Millennium Management LLC grew its position in Schrödinger by 2,868.8% during the second quarter. Millennium Management LLC now owns 487,831 shares of the company’s stock worth $9,435,000 after buying an additional 471,399 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in Schrödinger by 39.6% during the third quarter. Stephens Investment Management Group LLC now owns 1,539,870 shares of the company’s stock valued at $28,565,000 after acquiring an additional 436,789 shares during the period. Finally, Barclays PLC raised its holdings in Schrödinger by 421.6% in the 3rd quarter. Barclays PLC now owns 107,554 shares of the company’s stock valued at $1,995,000 after acquiring an additional 86,933 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.